journal cover

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

Annals of the Rheumatic Diseases

Mar 3, 2007

G R BurmesterHartmut Kupper

Abstract

To evaluate the safety and effectiveness of adalimumab alone or in combination with standard disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA). Patients with active RA despite treatment with DMARDs or prior treatment with a tumour necrosis fac...read more

Mentioned in this Paper

Monoclonal Antibodies
Antirheumatic Drugs, Disease-Modifying
Tumor Necrosis Factor-alpha
Humira
Antagonist Muscle Action
Tumor Lysis Syndrome
Toxic Effect of Formaldehyde
Severity of Illness Index
Polychemotherapy
Adverse Event
106
Paper Details
References
  • References33
  • Citations94
1234
  • References33
  • Citations94
12345...

Similar Papers Found In These Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Systemic Lupus Erythematosus

Systemic lupus erythematosus is an autoimmune disorder which can affect and damage any organ system in the body. It has a diverse range of immunological manifestations and is more prominent in young women, with the exact etiology still unknown. Here is the latest research on systemic lupus erythematosus.

Immunomodulating Agents

Immunomodulating agents are substances that stimulate or suppresse the immune system and may help the body combat againsts cancer, infection, or other diseases. Discover the latest research on immunomodulating agents here.

Malaria Vaccines

Research for development of a malaria vaccine is currently underway to find an effective modality to control and eliminate the transmission of malaria. To date, no vaccine has been found to be efficacious in fighting against malaria. Here is the latest research on malaria vaccines.

© 2020 Meta ULC. All rights reserved

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

Annals of the Rheumatic Diseases

Mar 3, 2007

G R BurmesterHartmut Kupper

PMID: 17329305

DOI: 10.1136/ard.2006.066761

Abstract

To evaluate the safety and effectiveness of adalimumab alone or in combination with standard disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA). Patients with active RA despite treatment with DMARDs or prior treatment with a tumour necrosis fac...read more

Mentioned in this Paper

Monoclonal Antibodies
Antirheumatic Drugs, Disease-Modifying
Tumor Necrosis Factor-alpha
Humira
Antagonist Muscle Action
Tumor Lysis Syndrome
Toxic Effect of Formaldehyde
Severity of Illness Index
Polychemotherapy
Adverse Event
106

Related Papers

Paper Details
References
  • References33
  • Citations94
1234
  • References33
  • Citations94
12345...
/papers/adalimumab-alone-and-in-combination-with-disease-m/17329305